Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial

Jin Lu, Jae H Lee, Shang-Yi Huang, Lugui Qiu, Je-Jung Lee, Ting Liu, Sung-Soo Yoon, Kihyun Kim, Zhi X Shen, Hyeon S Eom, Wen M Chen, Chang K Min, Hyo J Kim, Jeong O Lee, Jae Y Kwak, Wai Yiu, Guang Chen, Annette Ervin-Haynes, Cyrille Hulin, Thierry Facon, Jin Lu, Jae H Lee, Shang-Yi Huang, Lugui Qiu, Je-Jung Lee, Ting Liu, Sung-Soo Yoon, Kihyun Kim, Zhi X Shen, Hyeon S Eom, Wen M Chen, Chang K Min, Hyo J Kim, Jeong O Lee, Jae Y Kwak, Wai Yiu, Guang Chen, Annette Ervin-Haynes, Cyrille Hulin, Thierry Facon

Abstract

The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low-dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Given genetic differences between Asian and Western populations, this subanalysis of the FIRST trial examined the safety and efficacy of Rd (given continuously or for 18 cycles [Rd18]) and MPT (melphalan, prednisone, thalidomide) in 114 Asian patients from Mainland China, South Korea and Taiwan. Efficacy and safety with Rd continuous in Asian patients were consistent with those in the overall study population. The overall response rates were 77·8% for Rd continuous, 57·5% for MPT and 65·8% for Rd18. The risk of progression or death was reduced by 39% with Rd continuous versus MPT and by 35% with Rd continuous versus Rd18. Rd continuous improved the 3-year survival rate compared with MPT (70·2% vs. 56·4%) and Rd18 (58·1%). Common grade 3/4 adverse events in the Rd continuous and MPT arms were neutropenia (25·0% vs. 43·6%), infection (19·4% vs. 28·2%) and anaemia (19·4% vs. 15·4%), respectively. Thromboembolic event rates were low, and no second primary malignancies were observed. Rd continuous is safe and effective in transplant-ineligible Asian patients with NDMM.

Keywords: Asia; lenalidomide; multiple myeloma; newly diagnosed; transplant-ineligible.

© 2017 The Authors. British Journal of Haematology Published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Progression‐free survival and overall survival in the Asian subpopulation (A and B, respectively). NE, not estimable; MPT, melphalan, prednisone, thalidomide; Rd cont, lenalidomide plus low‐dose dexamethasone until disease progression; Rd18, lenalidomide plus low‐dose dexamethasone for 18 cycles.

References

    1. Attal, M. , Lauwers‐Cances, V. , Hulin, C. , Facon, T. , Caillot, D. , Escoffre, M. , Arnulf, B. , Macro, M. , Belhadj, K. , Garderet, L. , Roussel, M. , Mathiot, C. , Avet‐Loiseau, H. , Munshi, N.C. , Richardson, P.G. , Anderson, K.C. , Harousseau, J.L. & Moreau, P. (2015) Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone du Myelome (IFM/DFCI 2009 trial). Blood (ASH Annual Meeting Abstracts), 126, 391.
    1. Benboubker, L. , Dimopoulos, M.A. , Dispenzieri, A. , Catalano, J. , Belch, A.R. , Cavo, M. , Pinto, A. , Weisel, K. , Ludwig, H. , Bahlis, N. , Banos, A. , Tiab, M. , Delforge, M. , Cavenagh, J. , Geraldes, C. , Lee, J.J. , Chen, C. , Oriol, A. , de la Rubia, J. , Qiu, L. , White, D.J. , Binder, D. , Anderson, K. , Fermand, J.P. , Moreau, P. , Attal, M. , Knight, R. , Chen, G. , Van Oostendorp, J. , Jacques, C. , Ervin‐Haynes, A. , Avet‐Loiseau, H. , Hulin, C. & Facon, T. ; FIRST Trial Team . (2014) Lenalidomide and dexamethasone in transplant‐ineligible patients with myeloma. The New England Journal of Medicine, 371, 906–917.
    1. Dimopoulos, M.A. , Oriol, A. , Nahi, H. , San Miguel, J. , Bahlis, N.J. , Rabin, N. , Orlowski, R. , Komarnicki, M. , Suzuki, K. , Plesner, T. , Samoilova, O.S. , Yoon, S.S. , Yehuda, D.B. , Richardson, P.G. , Goldschmidt, H. , Reece, D. , Khokhar, N. , O'Rourke, L. , Chiu, C. , Qin, X. , Guckert, M. , Ahmadi, T. & Moreau, P. (2016) An open‐label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX. Haematologica (EHA Abstracts), 101(s1), Abstract LB2238.
    1. Durie, B.G.M. , Harousseau, J. , Miguel, J.S. , Bladé, J. , Barlogie, B. , Anderson, K. , Gertz, M. , Dimopoulos, M. , Westin, J. , Sonneveld, P. , Ludwig, H. , Gahrton, G. , Beksac, M. , Crowley, J. , Belch, A. , Boccadaro, M. , Turesson, I. , Joshua, D. , Vesole, D. , Kyle, R. , Alexanian, R. , Tricot, G. , Attal, M. , Merlini, G. , Powles, R. , Richardson, P. , Shimizu, K. , Tosi, P. , Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467–1473.
    1. Durie, B.G.M. , Hoering, A. , Rajkumar, S.V. , Abidi, M.H. , Epstein, J. , Kahanic, S.P. , Thakuri, M.C. , Reu, F.J. , Reynolds, C.M. , Sexton, R. , Orlowski, R.Z. , Barlogie, B. & Dispenzieri, A. (2015) Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777. Blood, 126, 25.
    1. Ferlay, J. , Soerjomataram, I. , Ervik, M. , Dikshit, R. , Eser, S. , Mathers, C. , Rebelo, M. , Parkin, D.M. , Forman, D. & Bray, F. (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase no. 11. International Agency for Research on Cancer, lyon: Available from: . Accessed 31 October 2016.
    1. Gonsalves, W.I. , Leung, N. , Rajkumar, S.V. , Dispenzieri, A. , Lacy, M.Q. , Hayman, S.R. , Buadi, F.K. , Dingli, D. , Kapoor, P. , Go, R.S. , Lin, Y. , Russell, S.J. , Lust, J.A. , Zeldenrust, S. , Kyle, R.A. , Gertz, M.A. & Kumar, S.K. (2015) Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 5, e296.
    1. Huang, S.Y. , Yao, M. , Tang, J.L. , Lee, W.C. , Tsay, W. , Cheng, A.L. , Wang, C.H. , Chen, Y.C. , Shen, M.C. & Tien, H.F. (2007) Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years. Cancer, 110, 896–905.
    1. Kang, S.H. , Kim, T.Y. , Kim, H.Y. , Yoon, J.H. , Cho, H.I. , Yoon, S.S. , Kang, D.H. , Suh, C.W. , Lee, J.H. & Lee, D.S. (2008) Protective role of CYP1A1*2A in the development of multiple myeloma. Acta Haematologica, 119, 60–64.
    1. Kim, K. , Lee, J.H. , Kim, J.S. , Min, C.K. , Yoon, S.S. , Shimizu, K. , Chou, T. , Kosugi, H. , Suzuki, K. , Chen, W. , Hou, J. , Lu, J. , Huang, X.J. , Huang, S.Y. , Chng, W.J. , Tan, D. , Teoh, G. , Chim, C.S. , Nawarawong, W. , Siritanaratkul, N. & Durie, B.G. (2014) Clinical profiles of multiple myeloma in Asia‐an Asian Myeloma Network Study. American Journal of Hematology, 89, 751–756.
    1. Lee, J.H. , Lee, D.S. , Lee, J.J. , Chang, Y.H. , Jin, J.Y. , Jo, D.Y. , Bang, S.M. , Kim, H.J. , Kim, J.S. , Kim, K. , Eom, H.S. , Min, C.K. , Yoon, S.S. , Kim, S.H. , Suh, C. & Cho, K.S. ; Korean Multiple Myeloma Working Party . (2010) Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. International Journal of Hematology, 92, 52–57.
    1. Lonial, S. , Dimopoulos, M. , Palumbo, A. , White, D. , Grosicki, S. , Spicka, I. , Walter‐Croneck, A. , Moreau, P. , Mateos, M.V. , Magen, H. , Belch, A. , Reece, D. , Beksac, M. , Spencer, A. , Oakervee, H. , Orlowski, R.Z. , Taniwaki, M. , Rollig, C. , Einsele, H. , Wu, K.L. , Singhal, A. , San‐Miguel, J. , Matsumoto, M. , Katz, J. , Bleickardt, E. , Poulart, V. , Anderson, K.C. & Richardson, P. ; ELOQUENT‐2 Investigators . (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. The New England Journal of Medicine, 373, 621–631.
    1. Lu, J. , Lu, J. , Chen, W. , Huo, Y. , Huang, X. & Hou, J. ; Chinese Medical Doctor Association Hematology Branch . (2014) Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer Journal, 4, e239.
    1. Mateos, M.V. , Ocio, E.M. , Paiva, B. , Rosinol, L. , Martinez‐Lopez, J. , Blade, J. , Lahuerta, J.J. , Garcia‐Sanz, R. & San Miguel, J.F. (2015) Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Reviews, 29, 387–403.
    1. Moreau, P. , Attal, M. & Facon, T. (2015) Frontline therapy of multiple myeloma. Blood, 125, 3076–3084.
    1. Moreau, P. , Masszi, T. , Grzasko, N. , Bahlis, N.J. , Hansson, M. , Pour, L. , Sandhu, I. , Ganly, P. , Baker, B.W. , Jackson, S.R. , Stoppa, A.M. , Simpson, D.R. , Gimsing, P. , Palumbo, A. , Garderet, L. , Cavo, M. , Kumar, S. , Touzeau, C. , Buadi, F.K. , Laubach, J.P. , Berg, D.T. , Lin, J. , Di Bacco, A. , Hui, A.M. , van de Velde, H. & Richardson, P.G. ; TOURMALINE‐MM1 Study Group . (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. The New England Journal of Medicine, 374, 1621–1634.
    1. National Cancer Institute . (2006) Common terminology criteria for adverse events (CTCAE) version 3.0. Available from: . Accessed 31 October 2016.
    1. National Comprehensive Cancer Network . (2016) Clinical practice guidelines in oncology: Multiple myeloma (version 1.2017). Available from: . Accessed 31 October 2016.
    1. Palumbo, A. & Anderson, K. (2011) Multiple myeloma. The New England Journal of Medicine, 364, 1046–1060.
    1. Palumbo, A. , Rajkumar, S.V. , San Miguel, J.F. , Larocca, A. , Niesvizky, R. , Morgan, G. , Landgren, O. , Hajek, R. , Einsele, H. , Anderson, K.C. , Dimopoulos, M.A. , Richardson, P.G. , Cavo, M. , Spencer, A. , Stewart, A.K. , Shimizu, K. , Lonial, S. , Sonneveld, P. , Durie, B.G. , Moreau, P. & Orlowski, R.Z. (2014) International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem‐cell transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 32, 587–600.
    1. Ramamoorthy, A. , Pacanowski, M.A. , Bull, J. & Zhang, L. (2015) Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clinical Pharmacology and Therapeutics, 97, 263–273.
    1. Shyu, V.B. , Wang, P. & Chu, P. (2009) Low incidence of venous thromboembolism in Asian myeloma patients treated with thalidomide plus dexamethasone. Asia‐Pacific Journal of Oncology and Hematology, 2, 41.
    1. Stewart, A.K. , Rajkumar, S.V. , Dimopoulos, M.A. , Masszi, T. , Spicka, I. , Oriol, A. , Hajek, R. , Rosinol, L. , Siegel, D.S. , Mihaylov, G.G. , Goranova‐Marinova, V. , Rajnics, P. , Suvorov, A. , Niesvizky, R. , Jakubowiak, A.J. , San‐Miguel, J.F. , Ludwig, H. , Wang, M. , Maisnar, V. , Minarik, J. , Bensinger, W.I. , Mateos, M.V. , Ben‐Yehuda, D. , Kukreti, V. , Zojwalla, N. , Tonda, M.E. , Yang, X. , Xing, B. , Moreau, P. & Palumbo, A. ; ASPIRE Investigators . (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine, 372, 142–152.
    1. Tan, D. , Chng, W.J. , Chou, T. , Nawarawong, W. , Hwang, S.Y. , Chim, C.S. , Chen, W. , Durie, B.G. & Lee, J.H. (2013) Management of multiple myeloma in Asia: resource‐stratified guidelines. The Lancet. Oncology, 14, e571–e581.
    1. Turesson, I. , Velez, R. , Kristinsson, S.Y. & Landgren, O. (2010) Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clinic Proceedings, 85, 225–230.
    1. Yasuda, S.U. , Zhang, L. & Huang, S.M. (2008) The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clinical Pharmacology and Therapeutics, 84, 417–423.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit